SHR 3821
Alternative Names: SHR-3821Latest Information Update: 07 Feb 2025
At a glance
- Originator Suzhou Suncadia Biopharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 13 Nov 2024 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (Parenteral) (NCT06618651)
- 08 Oct 2024 Preclinical trials in Solid tumours in China (Parenteral), prior to October 2024
- 26 Sep 2024 Suzhou Suncadia Biopharmaceuticals plans a phase I trial for Solid tumours (Late-stage disease) in China (Parenteral, Injection) in November 2024(NCT06618651)